SphingoTec Expands Management Team and Appoints new CFO

Written by: Editor
Published on: 10 Jun 2021

Sphingotec

  • Dr. Angelo Moesslang was named CFO and Managing Director of SphingoTec.
  • The company has developed innovative biomarkers for critical care settings and makes them available on their point of care platform, Nexus IB10.
  • The new senior leadership addition broadens SphingoTec’s core capabilities in response to the anticipated significant expansion of its activities.

Hennigsdorf/Berlin, Germany, June 10, 2021 – Diagnostics company SphingoTec GmbH (“SphingoTec”) announces the appointment of Dr. Angelo Moesslang as new chief financial officer (CFO) and managing director.

SphingoTec develops and markets innovative in vitro diagnostic solutions for novel biomarkers that support personalized medicine in critical care conditions. Sphingotec is a fully integrated diagnostics company: the innovative biomarkers are commercially available on the proprietary point of care platform Nexus IB10. Following a successful implementation of the biomarkers in clinical routine, the company is now oriented towards geographical expansion and commercial growth.

Dr. Angelo Moesslang commented, “I was drawn to SphingoTec’s vision and focus of translating the science of novel biomarkers into clinical routine. I am excited to join such an innovative young company, ideally positioned for growth. This new role will allow me to leverage my expertise, contribute to the commercialization effort and continue the initiatives of improving patient management in critical care with innovative diagnostic solutions.”

Dr. Moesslang has more than 20 years of global healthcare and finance leadership experience. Prior to joining SphingoTec he served as CEO of a US-based medical device startup and held various executive roles with the Fresenius Group in Europe, Asia, and the US, most recently CFO of Fresenius Medical Care North America.

Dr. Andreas Bergmann, CEO and founder of SphingoTec added, “With the international commercialization of our validated biomarkers and established point of care platform, we are now bringing diagnostic breakthroughs to critical care clinicians. We are excited to welcome Mr. Moesslang, whose entrepreneurial spirit and energy will bring strategic value to our next stage of business development. “